Future Fund LLC Buys 31,818 Shares of GeneDx Holdings Corp. $WGS

Future Fund LLC boosted its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 264.0% during the first quarter, Holdings Channel reports. The institutional investor owned 43,871 shares of the company’s stock after buying an additional 31,818 shares during the period. Future Fund LLC’s holdings in GeneDx were worth $2,817,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Kestra Advisory Services LLC acquired a new stake in GeneDx during the fourth quarter worth approximately $27,000. Ramirez Asset Management Inc. bought a new stake in shares of GeneDx during the fourth quarter worth approximately $33,000. Greenline Wealth Management LLC acquired a new position in shares of GeneDx in the fourth quarter valued at approximately $33,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of GeneDx in the fourth quarter valued at approximately $35,000. Finally, Quarry LP increased its stake in shares of GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after purchasing an additional 209 shares during the period. 61.72% of the stock is owned by institutional investors.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Neutral Sentiment: Several firms, including Kahn Swick & Foti, Faruqi & Faruqi, Rosen, Hagens Berman, Robbins Geller, and others, reminded investors that the deadline to seek lead-plaintiff status in the GeneDx securities class action is August 3, 2026. Article Title
• Neutral Sentiment: Hagens Berman said it is investigating allegations that GeneDx and executives misled investors about the Fabric Genomics acquisition and expected synergies, citing the company’s sharp stock decline after its Q1 2026 results and a $31.2 million impairment charge. Article Title
• Neutral Sentiment: GeneDx also announced it will report second-quarter 2026 financial results on August 3, giving investors a near-term catalyst for the stock beyond the litigation headlines. Article Title

GeneDx Trading Up 2.9%

Shares of GeneDx stock opened at $63.48 on Friday. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -23.69 and a beta of 1.90. The firm’s 50-day moving average price is $56.56 and its two-hundred day moving average price is $74.83. GeneDx Holdings Corp. has a 12-month low of $32.21 and a 12-month high of $170.87.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The business had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same quarter in the prior year, the firm earned ($0.23) EPS. On average, analysts forecast that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Casdin Capital, Llc bought 50,000 shares of GeneDx stock in a transaction that occurred on Friday, June 5th. The shares were acquired at an average cost of $52.86 per share, for a total transaction of $2,643,000.00. Following the completion of the acquisition, the director directly owned 3,707,164 shares of the company’s stock, valued at approximately $195,960,689.04. The trade was a 1.37% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Keith A. Meister bought 46,273 shares of GeneDx stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average price of $38.91 per share, for a total transaction of $1,800,482.43. Following the completion of the acquisition, the director directly owned 4,784,570 shares of the company’s stock, valued at $186,167,618.70. The trade was a 0.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders purchased 2,256,420 shares of company stock worth $93,144,340 and sold 21,699 shares worth $1,295,646. Company insiders own 25.17% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on WGS shares. Wall Street Zen cut GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Guggenheim reaffirmed a “buy” rating and issued a $74.00 price objective (up from $70.00) on shares of GeneDx in a report on Monday, June 29th. Piper Sandler reiterated an “overweight” rating and set a $63.00 price objective (up from $50.00) on shares of GeneDx in a research report on Tuesday, June 23rd. Zacks Research downgraded GeneDx from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Finally, Canaccord Genuity Group set a $75.00 target price on shares of GeneDx and gave the company a “buy” rating in a research report on Tuesday, May 5th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and a consensus price target of $87.43.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.